The Global Health Body Sounds Concern Over Severe Lack of Obesity Medications
Less than 10% of patients who could benefit from obesity jabs such as Wegovy can access them, states the WHO as it issues its inaugural advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for broader and more equitable availability to GLP-1 medication.
According to estimates, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"The latest guidance affirms that obesity is a lifelong illness that can be addressed with comprehensive and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant barriers to universal access to the injections that can assist patients in reducing significant body mass, says the body.
Weight-Loss Drug Shortage
Even under the present most favorable scenario, the supply of GLP-1 therapies might only reach about 100 million people – less than 10% of the global need, per the WHO.
The guideline encourages governments and firms to expand access, via measures including voluntary licensing.
A patent on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is due to expire in multiple nations in 2026.
How Obesity Drugs Operate
These medications imitate a body's own hormone to reduce digestion speed, curb appetite and enhance satiety so people consume fewer calories.
Individuals commonly see weight reduction in the initial weeks of starting on the once-weekly jabs.
Evidence points to people may regain a significant portion a year later of halting the drug, when their typical food cravings return.
Being overweight or obese elevates your likelihood for developing medical conditions, including diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight concerns individuals in every country and was associated with 3.7 million fatalities worldwide in 2024, per the health agency.
